For the fourth year in a row, Massachusetts blew past its own 3.6% health care cost-growth benchmark in 2024, with spending rising about 5.7% to roughly $83.3 billion. Hospitals and prescription drugs once again soaked up a big share of that money, tightening affordability pressures on families, employers and the state budget.
The latest numbers come from a state report highlighted by the Boston Business Journal, which noted that 2024 was the fourth straight year spending growth overshot the benchmark. According to the outlet, pharmaceutical costs and hospital spending were the main culprits, extending a multi-year streak of elevated growth that state watchdogs say will require a mix of regulatory action and market pressure.
What’s Driving Costs
The state’s Health Policy Commission has repeatedly flagged pharmacy costs, particularly the rapid rise of GLP‑1 medications, along with higher prices for hospital outpatient services, as the biggest recent contributors to overall growth. The commission reports that pharmacy spending net of rebates and hospital outpatient care added significantly to per-capita costs in the most recent period. Officials there warn that without targeted moves to rein in prices, insurance premiums and out-of-pocket costs are likely to keep climbing faster than many residents’ paychecks.
Longer Trend and State Data
Data from the Center for Health Information and Analysis show Massachusetts has been wrestling with above-benchmark growth for several years, with per-resident spending still well above the national average. CHIA’s analysis gives lawmakers and regulators the detailed numbers they need to pinpoint where prices and use of services are rising fastest. Those figures have become a fixture at the state’s annual benchmark hearings and guide the Health Policy Commission’s scrutiny of providers and insurers with persistently high growth.
Provider Perspective
Hospital and provider groups do not deny the spending surge, but they stress that the story looks different from inside the system. In a recent impact report, the Massachusetts Health & Hospital Association underscored hospitals’ role in the state economy and the billions they put into subsidized care, while urging policymakers not to push reforms so hard that they destabilize providers. The association argues that community benefits, research commitments and workforce investments are key pieces of the cost puzzle, even as health systems navigate inflation and ongoing staffing shortages.
What Comes Next
State leaders do not have many easy levers to pull. The Healey administration and the Division of Insurance have moved to cut back on administrative hassles like prior authorization, while the Health Policy Commission can put high-growth organizations on performance-improvement plans or send them for deeper review. Coverage rules and regulatory tweaks announced earlier this year are aimed at trimming delays and paperwork waste, even as the fight over broader price controls and drug-pricing rules continues. For residents, that likely means more policy skirmishes and incremental fixes as the state tries to slow cost growth without undermining the care that helps keep Massachusetts at the top of national health rankings.
